株探米国株
日本語 英語
エドガーで原本を確認する
KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292025-03-122025-03-12



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2025
 
 
Kewaunee Scientific Corporation
(Exact name of registrant as specified in its charter)
 
Delaware   0-5286   38-0715562
(State or other jurisdiction of
incorporation or organization)
  (Commission File
Number)
  (IRS Employer
Identification No.)
2700 West Front Street
Statesville, NC 28677
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (704) 873-7202
N/A
(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $2.50 par value
KEQU The Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the On March 12, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2025.
Exchange Act. ☐
 
 






Item 2.02 Results of Operations and Financial Condition
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
   Description
99.1
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
  KEWAUNEE SCIENTIFIC CORPORATION
                             (Registrant)
Date: March 12, 2025   By /s/ Donald T. Gardner III
  Donald T. Gardner III
  Vice President, Finance
Chief Financial Officer




EX-99.1 2 prfy25q3earningsrelease.htm EX-99.1 Document

logo_stackedxdarka.jpg

Kewaunee Scientific Reports
Results for Third Quarter of Fiscal Year 2025

Exchange:    NASDAQ (KEQU)                Contact:    Donald T. Gardner III
                                    704/871-3274

STATESVILLE, N.C. March 12, 2025 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its third quarter ended January 31, 2025.

Fiscal Year 2025 Third Quarter Results:

Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter. EBITDA1 for the quarter was $3,734,000 compared to $4,414,000 for the prior year quarter. Diluted earnings per share were $0.45 compared to diluted earnings per share of $0.85 in the prior year quarter.

Within the third quarter there were costs associated with the acquisition and integration of Nu Aire by Kewaunee Scientific Corporation. Additionally, results were impacted by transaction accounting related to the write-up of various assets on Nu Aire's books. We believe communicating these impacts and reporting adjusted financial metrics helps investors better understand our financial performance.

Consolidated Results Adjusted for Professional and Other Fees Related to the Nu Aire Transaction, Integration, and Purchase Accounting - Acquisition, integration and purchase accounting costs in the aggregate in quarter three were a $2,514,000 impact to pre-tax earnings and a $1,994,000 impact to EBITDA. After adjusting for these costs, adjusted pre-tax earnings for the quarter were $3,789,000 compared to $3,515,000 for the prior year quarter, an increase of 7.8%. Adjusted net earnings were $3,258,000 compared to net earnings of $2,521,000 for the prior year quarter. Adjusted EBITDA for the quarter was $5,728,000 compared to $4,414,000 for the prior year quarter. Adjusted diluted earnings per share were $1.09 compared to diluted earnings per share of $0.85 in the prior year quarter. Further details are presented in the Adjusted Consolidated Statement of Operations Reconciliation schedule.

The Company’s order backlog was $221.6 million on January 31, 2025, as compared to $152.3 million on January 31, 2024, and $155.6 million on April 30, 2024.

Nu Aire Acquisition Update - Kewaunee successfully completed the acquisition of Nu Aire, Inc. on November 1, 2024, marking a significant milestone in our strategic growth initiatives. This quarter represents the first time Nu Aire's financial results will be integrated into
1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

CORPORATE OFFICES ● P. O. BOX 1842, STATESVILLE, NORTH CAROLINA 28687-1842 ● 2700 WEST FRONT STREET, STATESVILLE, NORTH CAROLINA 28677-2927
PHONE 704-873-7202 ● FAX 704-873-1275


Kewaunee's consolidated financial statements and order backlog, with its performance reported within the Company's Domestic segment.

Domestic Segment - Domestic sales for the quarter were $51,976,000, an increase of 63.6% from sales of $31,774,000 in the prior year quarter. Domestic segment net earnings were $2,876,000 compared to $2,633,000 in the prior year quarter. Domestic segment EBITDA was $5,249,000 compared to $3,832,000 for the prior year quarter. The increase in Domestic sales and earnings was driven by higher manufacturing volumes than the prior year period and the incorporation of Nu Aire's results.

International Segment - International sales for the quarter were $15,191,000, an increase of 1.2% from sales of $15,004,000 in the prior year quarter. International segment net earnings were $476,000 compared to $923,000 in the prior year quarter. International segment EBITDA was $760,000 compared to $1,676,000 for the prior year quarter. Kewaunee's International segment continues to be challenged by customer site delays impacting billings.

Corporate Segment – Corporate segment pre-tax net loss was $3,025,000 for the quarter, as compared to a pre-tax net loss of $1,069,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,275,000) compared to corporate segment EBITDA of ($1,094,000) for the prior year quarter. The change in EBITDA was primarily driven by an increase in professional service and other fees during the quarter related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024, and costs incurred related to Sarbanes-Oxley 404(b) compliance readiness.

Total cash on hand on January 31, 2025, was $12,335,000, as compared to $25,938,000 on April 30, 2024. Working capital was $58,441,000, as compared to $54,014,000 at the end of the third quarter last year and $56,037,000 on April 30, 2024.

The Company had short-term debt of $1,131,000 as of January 31, 2025, as compared to $3,099,000 on April 30, 2024. Long-term debt was $65,819,000 on January 31, 2025, as compared to $28,479,000 on April 30, 2024. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $27,604,000 of the long-term debt on January 31, 2025, and $28,133,000 of the long-term debt on April 30, 2024. Long-term debt, net of the sale-leaseback transaction, was $38,215,000 on January 31, 2025, as compared to $346,000 on April 30, 2024. The Company’s debt-to-equity ratio on January 31, 2025, was 1.29-to-1, as compared to 0.70-to-1 on April 30, 2024. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on January 31, 2025, was 0.84-to-1, as compared to 0.20-to-1 on April 30, 2024.

"Kewaunee delivered another strong quarter, demonstrating once again our positive momentum in the marketplace and our continued operational performance improvement," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Our strategy to emphasize investments in our manufacturing assets, while strengthening our dealer and distribution relationships is working."

"In our Domestic segment, we achieved solid gains compared to the prior year. These gains were driven by sustained product demand in the U.S., where we leverage our market position as the industry's leader."

"In India, where our backlog is at a record high, revenue has been slowed due to construction site delays. We are working closely with our customers to ensure seamless execution when project sites are ready. This will result in favorable revenue and earnings for us."

Hull continued, "Kewaunee's backlog stands at a robust $222 million, highlighting the strength, stability, and diversity of the markets we serve. Our products support a broad range of critical industries - including life sciences, industrial, healthcare, pharmacy, education, petrochemical, and government research. These sectors are foundational to economic progress, scientific discovery, and innovation, and they benefit from long-term structural growth trends fueled by both private and public investment.



Our strong backlog is a testament to Kewaunee's ability to meet evolving customer needs and reinforces our position as a trusted partner in advancing global research and innovation."

"Over the past five years, we have taken deliberate steps to strengthen our supply chain and mitigate risks to ensure resiliency amid market fluctuations. As the largest U.S.-based manufacturer of laboratory products and technical furniture, Kewaunee is uniquely positioned to provide stability and certainty to customers requiring reliable, domestically produced solutions. Additionally, we have built a robust and diversified global supply chain, ensuring access to critical materials through multiple sourcing strategies. These strategic initiatives enhance our ability to consistently deliver high-quality products while mitigating against supply chain disruptions, tariffs, and other external challenges."

"To provide greater transparency into our financial performance, we have included an exhibit detailing the reconciliation from EBITDA to adjusted EBITDA. This analysis isolates transaction, integration, and other related costs, providing a clearer picture of Kewaunee's ongoing earnings power post-integration of the Nu Aire acquisition."

"Looking ahead, we are focused on delivering a strong finish to fiscal year 2025. Our teams remain committed to operational excellence, customer success, and driving sustainable growth. We continue to invest in our partnerships, ensuring our channel partners have the support they need to win in the marketplace. With strong fundamentals, a growing backlog, and a clear strategic vision, Kewaunee is well-positioned to capitalize on future opportunities and create lasting value for our shareholders."




EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation
(Unaudited)
($ in thousands)
Quarter Ended January 31, 2024 Domestic International Corporate Consolidated
Net Earnings (Loss) $ 2,633  $ 923  $ (1,035) $ 2,521 
Add/(Less):
Interest Expense 321  72  18  411 
Interest Income —  (220) (97) (317)
Income Taxes 220  796  (34) 982 
Depreciation and Amortization 658  105  54  817 
EBITDA $ 3,832  $ 1,676  $ (1,094) $ 4,414 
Quarter Ended January 31, 2025 Domestic International Corporate Consolidated
Net Earnings (Loss) $ 2,876  $ 476  $ (1,998) $ 1,354 
Add/(Less):
Interest Expense 322  26  789  1,137 
Interest Income (1) (130) (81) (212)
Income Taxes 638  281  (1,027) (108)
Depreciation and Amortization 1,414  107  42  1,563 
EBITDA $ 5,249  $ 760  $ (2,275) $ 3,734 
Professional & Other Fees2
1,012  —  982  1,994 
Adjusted EBITDA $ 6,261  $ 760  $ (1,293) $ 5,728 
Year to Date January 31, 2024 Domestic International Corporate Consolidated
Net Earnings (Loss) $ 8,398  $ 1,917  $ (2,588) $ 7,727 
Add/(Less):
Interest Expense 1,024  143  46  1,213 
Interest Income —  (638) (120) (758)
Income Taxes 2,365  2,257  (728) 3,894 
Depreciation and Amortization 1,853  302  150  2,305 
EBITDA $ 13,640  $ 3,981  $ (3,240) $ 14,381 
Year to Date January 31, 2025 Domestic International Corporate Consolidated
Net Earnings (Loss) $ 10,271  $ 1,295  $ (5,011) $ 6,555 
Add/(Less):
Interest Expense 1,176  66  809  2,051 
Interest Income (1) (437) (410) (848)
Income Taxes 2,643  807  (2,450) 1,000 
Depreciation and Amortization 2,736  317  131  3,184 
EBITDA $ 16,825  $ 2,048  $ (6,931) $ 11,942 
Professional & Other Fees3
1,012  —  3,253  4,265 
Adjusted EBITDA $ 17,837  $ 2,048  $ (3,678) $ 16,207 

2 Professional and other fees incurred during the three months ended January 31, 2025 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024, and related purchase accounting
3 Professional and other fees incurred during the nine months ended January 31, 2025 related to the Company's acquisition of Nu Aire and related purchase accounting



Adjusted Consolidated Statement of Operations Reconciliation
(Unaudited)
($ in thousands, except per share amounts)
  Three Months Ended January 31,
  As Reported 2025
Professional & Other Fees4
Adjusted
2025
2024
Net sales $ 67,167  $ $ 67,167 $ 46,778 
Cost of products sold 48,788  854 47,934 34,749 
Gross profit 18,379  854 19,233 12,029 
Operating expenses 16,129  1,660 14,469 8,223 
Operating profit 2,250  2,514 4,764 3,806 
Pension expense —  (41)
Other income, net
162  162 161 
Interest expense (1,137) (1,137) (411)
Profit before income taxes 1,275  2,514  3,789  3,515 
Income tax (benefit) expense
(108) 610  502  982 
Net earnings 1,383  1,904 3,287 2,533 
Less: Net earnings attributable to the non-controlling interest 29  29 12 
Net earnings attributable to Kewaunee Scientific Corporation $ 1,354  $ 1,904 $ 3,258 $ 2,521 
Net earnings per share attributable to Kewaunee Scientific Corporation stockholders
Basic $ 0.47  $ 0.66  $ 1.13  $ 0.87 
Diluted $ 0.45  $ 0.64  $ 1.09  $ 0.85 
  Nine Months Ended January 31,
  As Reported 2025
Professional & Other Fees5
Adjusted
2025
2024
Net sales $ 163,324  $ $ 163,324 $ 147,053 
Cost of products sold 118,505  854 117,651 109,642 
Gross profit 44,819  854 45,673 37,411 
Operating expenses 35,560  3,606 31,954 24,688 
Operating profit 9,259  4,460 13,719 12,723 
Pension expense —  (122)
Other income, net 428  324 752 384 
Interest expense (2,051) (2,051) (1,213)
Profit before income taxes 7,636  4,784  12,420  11,772 
Income tax expense 1,000  1,161  2,161  3,894 
Net earnings 6,636  3,623 10,259 7,878 
Less: Net earnings attributable to the non-controlling interest 81  81 151 
Net earnings attributable to Kewaunee Scientific Corporation $ 6,555  $ 3,623 $ 10,178 $ 7,727 
Net earnings per share attributable to Kewaunee Scientific Corporation stockholders
Basic $ 2.29  $ 1.27  $ 3.55  $ 2.68 
Diluted $ 2.20  $ 1.22  $ 3.42  $ 2.64 
4 Professional and other fees incurred during the three months ended January 31, 2025 related to the Company's acquisition of Nu Aire and related purchase accounting, including the estimated tax impact
5 Professional and other fees incurred during the nine months ended January 31, 2025 related to the Company's acquisition of Nu Aire and related purchase accounting and costs incurred related to the early termination of the Company's Revolving Credit Facility, including the estimated tax impact of both transactions



About Non-GAAP Measures

The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the acquisition of Nu Aire, Inc. and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's acquisition of Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization or the professional fees not related to our core business incurred during the current period, which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company’s operating performance, or as an alternative to operating cash flows as a measure of liquidity.

About Kewaunee Scientific

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company’s products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company’s corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. 

Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.

Learn more at the companies' websites, located at http://www.kewaunee.com and http://www.nuaire.com/.

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including



statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders’ interest. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2024, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.




Kewaunee Scientific Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
($ and shares in thousands, except per share amounts)

  Three Months Ended
January 31,
Nine Months Ended
January 31,
  2025 2024 2025 2024
Net sales $ 67,167  $ 46,778  $ 163,324  $ 147,053 
Cost of products sold 48,788  34,749  118,505  109,642 
Gross profit 18,379  12,029  44,819  37,411 
Operating expenses 16,129  8,223  35,560  24,688 
Operating profit 2,250  3,806  9,259  12,723 
Pension expense —  (41) —  (122)
Other income, net
162  161  428  384 
Interest expense (1,137) (411) (2,051) (1,213)
Profit before income taxes 1,275  3,515  7,636  11,772 
Income tax (benefit) expense
(108) 982  1,000  3,894 
Net earnings 1,383  2,533  6,636  7,878 
Less: Net earnings attributable to the non-controlling interest 29  12  81  151 
Net earnings attributable to Kewaunee Scientific Corporation
$ 1,354  $ 2,521  $ 6,555  $ 7,727 
Net earnings per share attributable to Kewaunee Scientific Corporation stockholders
Basic $ 0.47  $ 0.87  $ 2.29  $ 2.68 
Diluted $ 0.45  $ 0.85  $ 2.20  $ 2.64 
Weighted average number of common shares outstanding
Basic 2,872  2,893  2,864  2,885 
Diluted 2,995  2,965  2,979  2,927 





Kewaunee Scientific Corporation
Condensed Consolidated Balance Sheets
($ in thousands)

January 31, 2025 April 30, 2024
  (Unaudited)
Assets
Cash and cash equivalents $ 9,454  $ 23,267 
Restricted cash 2,881  2,671 
Receivables, less allowances 57,419  45,064 
Inventories 31,560  20,679 
Prepaid expenses and other current assets 7,298  5,136 
Total Current Assets 108,612  96,817 
Net Property, Plant and Equipment 23,849  17,649 
Right of use assets 13,974  7,454 
Deferred income taxes 3,883  7,401 
Net Intangible assets
18,216  — 
Goodwill
14,150  — 
Other assets 6,464  5,445 
Total Assets $ 189,148  $ 134,766 
Liabilities and Stockholders' Equity
Short-term borrowings $ 1,131  $ 3,099 
Current portion of lease obligations 3,497  2,234 
Current portion of financing liability 769  713 
Current portion of term loan
3,000  — 
Accounts payable 24,530  23,262 
Other current liabilities
17,244  11,472 
Total Current Liabilities 50,171  40,780 
Long-term portion of lease obligations 9,700  5,669 
Long-term portion of financing liability 26,835  27,420 
Long-term portion of seller note
23,463  — 
Long-term portion of term loan
11,500  — 
Other non-current liabilities 5,358  4,688 
Total Liabilities 127,027  78,557 
Kewaunee Scientific Corporation Equity 60,801  54,760 
Non-controlling interest 1,320  1,449 
Total Stockholders' Equity 62,121  56,209 
Total Liabilities and Stockholders' Equity $ 189,148  $ 134,766